Match!

The Gulf Familial Hypercholesterolemia Registry (Gulf FH): Design, Rationale and Preliminary Results

Published on Oct 5, 2018in Current Vascular Pharmacology2.583
· DOI :10.2174/1570161116666181005125459
Khalid Al-Rasadi19
Estimated H-index: 19
(Sultan Qaboos University),
Khalid F. AlHabib25
Estimated H-index: 25
(KSU: King Saud University)
+ 20 AuthorsHani Altaradi3
Estimated H-index: 3
(KSU: King Saud University)
Abstract
AIM: To determine the prevalence, genetic characteristics, current management and outcomes of familial hypercholesterolaemia (FH) in the Gulf region. METHOD: Adult (18-70 years) FH patients were recruited from 9 hospitals and centres across 5 Arabian Gulf countries. The study was divided into 4 phases and included patients from 3 different categories. In Phase 1, suspected FH patients (category 1) were collected according to the lipid profile and clinical data obtained through hospital record systems. In phase 2, patients from category 2 (patients with previous clinical diagnosis of FH) and category 1 were stratified into definitive, probable and possible FH according to the Dutch Lipid Clinic Network criteria. In phase 3, 500 patients with definitive and probable FH from categories 1 and 2 will undergo genetic testing for 4 common FH genes. In phase 4, these 500 patients with another 100 patients from category 3 (patients with previous genetic diagnosis of FH) will be followed for 1 year to evaluate clinical management and cardiovascular outcomes. The Gulf FH cohort was screened from a total of 34,366 patients attending out-patient clinics. RESULTS: The final Gulf FH cohort consisted of 3,317 patients (mean age: 47±12 years, 54% females). The number of patients with definitive FH is 203. In this initial phase of the study, the prevalence of (probable and definite) FH is 1/232. CONCLUSIONS: The prevalence of FH in the adult population of the Arabian Gulf region is high. The Gulf FH registry, a first-of-a-kind multi-national study in the Middle East region, will help in improving underdiagnosis and undertreatment of FH in the region.
  • References (0)
  • Citations (0)
References0
Newest
#1Amy C. SturmH-Index: 15
#2Joshua W. Knowles (Cardiovascular Institute of the South)H-Index: 43
Last. Daniel J. RaderH-Index: 140
view all 32 authors...
Abstract Although awareness of familial hypercholesterolemia (FH) is increasing, this common, potentially fatal, treatable condition remains underdiagnosed. Despite FH being a genetic disorder, genetic testing is rarely used. The Familial Hypercholesterolemia Foundation convened an international expert panel to assess the utility of FH genetic testing. The rationale includes the following: 1) facilitation of definitive diagnosis; 2) pathogenic variants indicate higher cardiovascular risk, which ...
32 CitationsSource
#1Khalid Al-Rasadi (Sultan Qaboos University)H-Index: 19
#2Ibrahim Al-Zakwani (Sultan Qaboos University)H-Index: 16
Last. Mohammad Zubaid (Kuniv: Kuwait University)H-Index: 21
view all 8 authors...
Background Information on the epidemiology of familial hypercholesterolemia (FH) in the Arabian Gulf region, which has an elevated rate of consanguinity and type II diabetes, is scarce. Objectives To assess the prevalence of FH, its management, and impact on atherosclerotic cardiovascular disease (ASCVD) outcomes in a multicenter cohort of Arabian Gulf patients with acute coronary syndrome (ACS). Methods Patients (N = 3224) hospitalized with ACS were studied. FH was diagnosed using the Dutch Lip...
8 CitationsSource
#1Isabelle Ruel (MUHC: McGill University Health Centre)H-Index: 20
#2Sumayah Aljenedil (MUHC: McGill University Health Centre)H-Index: 5
Last. Jacques Genest (MUHC: McGill University Health Centre)H-Index: 81
view all 19 authors...
BACKGROUND: Familial hypercholesterolemia (FH) is the most frequent genetic disorder seen clinically and is characterized by increased LDL cholesterol (LDL-C) (>95th percentile), family history of increased LDL-C, premature atherosclerotic cardiovascular disease (ASCVD) in the patient or in first-degree relatives, presence of tendinous xanthomas or premature corneal arcus, or presence of a pathogenic mutation in the LDLR , PCSK9 , or APOB genes. A diagnosis of FH has important clinical implicati...
16 CitationsSource
#2Turky H. AlmigbalH-Index: 5
Last. Khalid F. AlHabibH-Index: 25
view all 5 authors...
BACKGROUND: The scarcity of familial hypercholesterolemia (FH) cases reported in Saudi Arabia might be indicative of a lack of awareness of this common genetic disease among physicians. OBJECTIVE: To assess physicians' awareness, practice, and knowledge of FH in Saudi Arabia. METHODS: This is a cross-sectional study conducted among physicians at four tertiary hospitals in Riyadh, Saudi Arabia between March 2016 and May 2016 using a self-administered questionnaire. RESULTS: A total of 294 physici...
3 CitationsSource
BACKGROUND: Familial hypercholesterolemia (FH) is a life-threatening inherited condition. Untreated patients have the risk to develop raised plasma levels of cholesterol, atherosclerosis and cardiovascular disease (CVD). If diagnosed and treated early in life, the pathological consequences due to atherosclerosis could be avoided and patients with FH can have an anticipated normal life. Mounting evidence suggests that FH is underdiagnosed and undertreated in all populations. The underlying molecu...
3 CitationsSource
#1Matthew I. Bellgard (Murdoch University)H-Index: 34
#2Caroline E. Walker (Government of Western Australia)H-Index: 6
Last. Watts G.F. (UWA: University of Western Australia)H-Index: 84
view all 20 authors...
Familial Hypercholesterolemia (FH) is the most common and serious monogenic disorder of lipoprotein metabolism that leads to premature coronary heart disease. There are over 65,000 people estimated to have FH in Australia, but many remain undiagnosed. Patients with FH are often undertreated, but with early detection, cascade family testing and adequate treatment, patient outcomes can improve. Patient registries are key tools for providing new information on FH and enhancing care worldwide. The d...
11 CitationsSource
#1Pablo LázaroH-Index: 15
#2Leopoldo Pérez de Isla (Hospital Clínico San Carlos)H-Index: 32
Last. Pedro MataH-Index: 35
view all 13 authors...
Background Although familial hypercholesterolemia (FH) confers a high risk of coronary artery disease, most patients are undiagnosed, and little is known about the efficiency of genetic cascade screening programs at national level. Objective The aim of the study was to estimate the cost-effectiveness of a national genetic cascade screening program in Spain. Methods An economic evaluation was performed using a decision tree analysis. The choice in the decision tree was between implementation of t...
26 CitationsSource
#1Nasreen Al SayedH-Index: 1
#2Khalid Al Waili (Sultan Qaboos University)H-Index: 2
Last. Philip J. Barter (UNSW: University of New South Wales)H-Index: 86
view all 14 authors...
Abstract Background Plasma lipid disorders are key risk factors for the development of atherosclerotic cardiovascular disease (ASCVD) and are prevalent in the Middle East, with rates increasing in recent decades. Despite this, no region-specific guidelines for managing plasma lipids exist and there is a lack of use of guidelines developed in other regions. Methods A multidisciplinary panel of regional experts was convened to develop consensus clinical recommendations for the management of plasma...
1 CitationsSource
#1Khalid Al Rasadi (Sultan Qaboos University)H-Index: 4
#2Wael Almahmeed (Cleveland Clinic)H-Index: 26
Last. Philip J. Barter (UNSW: University of New South Wales)H-Index: 86
view all 11 authors...
Abstract The increase in the cardiovascular disease (CVD)-associated mortality rate in the Middle East (ME) is among the highest in the world. The aim of this article is to review the current prevalence of dyslipidaemia and known gaps in its management in the ME region, and to propose initiatives to address the burden of dyslipidaemia. Published literature on the epidemiology of dyslipidaemia in the ME region was presented and discussed at an expert meeting that provided the basis of this review...
10 CitationsSource
#1Lidewij HennemanH-Index: 27
#2Colleen M. McBride (Emory University)H-Index: 54
Last. Nadeem Qureshi (VUmc: VU University Medical Center)H-Index: 25
view all 5 authors...
Familial hypercholesterolemia (FH), an autosomal dominant atherosclerotic disease, is a common monogenic subtype of cardiovascular disease. Patients with FH suffer an increased risk of early onset heart disease. Early identification of abnormally elevated cholesterol signpost clinicians to interventions that will significantly decrease risk of related morbidity and mortality. Cascade genetic testing can subsequently identify at-risk relatives. Accordingly, a number of screening approaches have b...
6 CitationsSource
Cited By0
Newest
#1Pengwei Hu (Imperial College London)H-Index: 1
#2Kanika I. Dharmayat (Imperial College London)H-Index: 2
Last. Antonio J. Vallejo-Vaz (Imperial College London)H-Index: 13
view all 9 authors...
Background: Contemporary studies suggest that familial hypercholesterolemia (FH) is more frequent than previously reported and increasingly recognized as affecting individuals of all ethnicities an...
1 CitationsSource